Most feasibility strategies rely on outdated assumptions—leading to costly delays, underperforming sites, and missed enrollment targets. This whitepaper reveals why traditional approaches fail and what’s needed to fix them.

• 43% of “participating” sites never enrol a single patient
• Site experience shows little correlation with performance
• Study-level averages mask critical inefficiencies

Discover how real-time, site-level data and predictive analytics can transform trial planning, improve enrolment accuracy, and reduce risk.

Download the full whitepaper to rethink feasibility and drive smarter, faster clinical trials.